0001567619-23-005257.txt : 20230317 0001567619-23-005257.hdr.sgml : 20230317 20230317161214 ACCESSION NUMBER: 0001567619-23-005257 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230315 FILED AS OF DATE: 20230317 DATE AS OF CHANGE: 20230317 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McClure Matthew W. CENTRAL INDEX KEY: 0001927121 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39617 FILM NUMBER: 23742689 MAIL ADDRESS: STREET 1: C/O ALIGOS THERAPEUTICS, INC. STREET 2: 1 CORPORATE DRIVE, 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aligos Therapeutics, Inc. CENTRAL INDEX KEY: 0001799448 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE CORPORATE DR., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (800) 466-6059 MAIL ADDRESS: STREET 1: ONE CORPORATE DR., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc1.xml FORM 4 X0306 4 2023-03-15 0 0001799448 Aligos Therapeutics, Inc. ALGS 0001927121 McClure Matthew W. C/O ALIGOS THERAPEUTICS, INC. 1 CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Medical Officer Stock Option (Right to Buy) 1.34 2023-03-15 4 A 0 75000 0 A 2033-03-15 Common Stock 75000 75000 D 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. /s/ Lucinda Y. Quan, as attorney-in fact for Matthew W. McClure 2023-03-17